1-20 of 24
Urs B. Hagemann
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 6033: Preclinical evaluation of an actinium-225 labeled PSMA-targeting small molecule (225Ac-PSMA-Trillium (BAY 3563254)) for the treatment of metastatic castration resistant prostate cancer (mCRPC)

Sabine Zitzmann-Kolbe, Alex Papple, Thorsten Poethko, Ingrid Moen, Christoph Schatz, Shawn Hillier, John W. Babich, Alan Cuthbertson, Urs B. Hagemann
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6033.
https://doi.org/10.1158/1538-7445.AM2024-6033
Published: 22 March 2024
View articletitled, Abstract 6033: Preclinical evaluation of an actinium-225 labeled PSMA-targeting small molecule (225Ac-PSMA-Trillium (BAY 3563254)) for the treatment of metastatic castration resistant prostate cancer (mCRPC)
Journal Articles

Abstract 688: Radium-223 in combination with darolutamide exhibits synergistic antitumor efficacy in LNCaP prostate cancer models

Christoph A. Schatz, Mari I. Suominen, Andreas Schlicker, Matias Knuuttila, Esa Alhoniemi, Sanna-Maria Käkönen, Bernard Haendler, Urs B. Hagemann, Arne Scholz
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 688.
https://doi.org/10.1158/1538-7445.AM2024-688
Published: 22 March 2024
View articletitled, Abstract 688: Radium-223 in combination with darolutamide exhibits synergistic antitumor efficacy in LNCaP prostate cancer models
Journal Articles

Abstract 5043: Radium-223 demonstrates increased antitumor activity in combination with 177Lu-PSMA-617 in the intratibial LNCaP xenograft model of bone metastatic prostate cancer

Arne Scholz, Matias Knuuttila, Justyna Zdrojewska, Mari I. Suominen, Esa Alhoniemi, Christoph A. Schatz, Sabine Zitzmann-Kolbe, Sanna-Maria Käkönen, Urs B. Hagemann
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5043.
https://doi.org/10.1158/1538-7445.AM2023-5043
Published: 04 April 2023
View articletitled, Abstract 5043: Radium-223 demonstrates increased antitumor activity in combination with 177Lu-PSMA-617 in the intratibial LNCaP xenograft model of bone metastatic prostate cancer
Journal Articles

Abstract 5047: PSMA-targeted actinium-225 conjugate (225Ac-pelgifatamab) potentiates the antitumor efficacy of darolutamide in androgen-dependent and -independent prostate cancer models

Christoph A. Schatz, Bernard Haendler, Sabine Zitzmann-Kolbe, Aasmund Larsen, Hartwig Hennekes, Carsten H. Nielsen, Maria Z. Alfsen, Alan Cuthbertson, Stefanie Hammer, Arne Scholz, Urs B. Hagemann
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5047.
https://doi.org/10.1158/1538-7445.AM2023-5047
Published: 04 April 2023
View articletitled, Abstract 5047: PSMA-targeted actinium-225 conjugate (225Ac-pelgifatamab) potentiates the antitumor efficacy of darolutamide in androgen-dependent and -independent prostate cancer models
Journal Articles

Abstract 1393: PSMA-Targeted Thorium Conjugate (BAY 2315497) and olaparib combination show synergistic anti-tumor activity in prostate cancer models

Christoph A. Schatz, Stefanie Hammer, Antje Wengner, Urs B. Hagemann, Dominik Mumberg, Arne Scholz
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): 1393.
https://doi.org/10.1158/1538-7445.AM2021-1393
Published: 01 July 2021
View articletitled, Abstract 1393: PSMA-Targeted Thorium Conjugate (BAY 2315497) and olaparib combination show synergistic anti-tumor activity in prostate cancer models
Journal Articles

Abstract 2257: Targeted thorium-227 conjugates demonstrate synergistic activity in combination with PD-L1 inhibitors

Urs B. Hagemann, Pascale Lejeune, Lisa Bartnitzky, Kathleen Stadelmann, Veronique Cruciani, Roger M. Bjerke, Sandra Berndt, Claudia Kamfenkel, Manuela Brand, Manuela Steinbach, Stefan Stargard, Christoph A. Schatz, Jenny Karlsson, Hartwig Hennekes, Alan S. Cuthbertson, Dominik Mumberg
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 2257.
https://doi.org/10.1158/1538-7445.AM2020-2257
Published: 15 August 2020
View articletitled, Abstract 2257: Targeted thorium-227 conjugates demonstrate synergistic activity in combination with PD-L1 inhibitors
Journal Articles

Abstract 5355: MSLN-targeted thorium-227 conjugate demonstrates increased antitumor activity in combination with bevacizumab and regorafenib

Urs B. Hagemann, Christine Ellingsen, Claudia Kamfenkel, Dieter Zopf, Jesper Fonslet, Carsten Nielsen, Hartwig Hennekes, Alan S. Cuthbertson, Dominik Mumberg
Journal: Cancer Research
Cancer Res (2020) 80 (16_Supplement): 5355.
https://doi.org/10.1158/1538-7445.AM2020-5355
Published: 15 August 2020
View articletitled, Abstract 5355: MSLN-targeted thorium-227 conjugate demonstrates increased antitumor activity in combination with bevacizumab and regorafenib
Journal Articles

Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation

Brian D. Yard, Priyanka Gopal, Kristina Bannik, Gerhard Siemeister, Urs B. Hagemann, Mohamed E. Abazeed
Journal: Cancer Research
Series: Author Choice
Cancer Res (2019) 79 (21): 5640–5651.
https://doi.org/10.1158/0008-5472.CAN-19-0859
Published: 01 November 2019
View articletitled, Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation
Open the PDF for Cellular and Genetic Determinants of the Sensitivity of Cancer to α-Particle Irradiation in another window
Includes: Supplementary data
Journal Articles

Abstract 3937: MSLN-TTC (BAY 2287411) demonstrates increased activity in comparison to standard of care chemotherapy in models of acquired drug resistance

Urs B. Hagemann, Sabine Zitzmann-Kolbe, Alexander Kristian, Carolyn Sperl, Christoph A. Schatz, Roger M. Bjerke, Alan S. Cuthbertson, Hartwig Hennekes, Karl Ziegelbauer, Dominik Mumberg
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3937.
https://doi.org/10.1158/1538-7445.AM2019-3937
Published: 01 July 2019
View articletitled, Abstract 3937: MSLN-TTC (BAY 2287411) demonstrates increased activity in comparison to standard of care chemotherapy in models of acquired drug resistance
Journal Articles

Abstract 3726: Preclinical activity of PSMA-TTC (BAY 2315497) in combination with androgen receptor antagonists in prostate cancer models

Stefanie Hammer, Urs B. Hagemann, Sabine Zitzmann-Kolbe, Aasmund Larsen, Chrstine Ellingsen, Oliver von Ahsen, Jenny Karlsson, Roger M. Bjerke, Olav B. Ryan, Pascale Lejeune, Hartwig Hennekes, Alan Cuthbertson, Dominik Mumberg
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3726.
https://doi.org/10.1158/1538-7445.AM2019-3726
Published: 01 July 2019
View articletitled, Abstract 3726: Preclinical activity of PSMA-TTC (BAY 2315497) in combination with androgen receptor antagonists in prostate cancer models
Journal Articles

Abstract 3926: MSLN-TTC (BAY 2287411) induces immunogenic cell death and secretion of pro-inflammatory cytokines in vitro and triggers an immune memory effect against a mouse tumor model

Urs B. Hagemann, Pascale LeJeune, Jenny Karlsson, Christoph A. Schatz, Alan S. Cuthbertson, Hartwig Hennekes, Karl Ziegelbauer, Dominik Mumberg
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 3926.
https://doi.org/10.1158/1538-7445.AM2019-3926
Published: 01 July 2019
View articletitled, Abstract 3926: MSLN-TTC (BAY 2287411) induces immunogenic cell death and secretion of pro-inflammatory cytokines in vitro and triggers an immune memory effect against a mouse tumor model
Journal Articles

Abstract 1141: Preclinical analysis of biodistribution and PET imaging of a zirconium-89 labeled PSMA-targeted antibody-chelator conjugate

Stefanie Hammer, Sabine Zitzmann-Kolbe, Felix Oden, Joerg Jannsen, Eva Bickel, Andre Mueller, Lothar Everz, Urs B. Hagemann, Jenny Karlsson, Olav B. Ryan, Hartwig Hennekes, Patricia E. Cole, Dominik Mumberg
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): 1141.
https://doi.org/10.1158/1538-7445.AM2019-1141
Published: 01 July 2019
View articletitled, Abstract 1141: Preclinical analysis of biodistribution and PET imaging of a zirconium-89 labeled PSMA-targeted antibody-chelator conjugate
Journal Articles

Abstract 855: Increased in vitro potency and in vivo efficacy of FGFR2-targeted thorium-227 conjugate (FGFR2-TTC) in combination with the ATR inhibitor BAY 1895344

Katrine Wickstroem, Urs B. Hagemann, Antje M. Wengner, Anette Sommer, Alexander Kristian, Christine Ellingsen, Roger M. Bjerke, Jenny Karlsson, Olav B. Ryan, Lars Linden, Bertolt Kreft, Dominik Mumberg, Hanno Wild, Karl Ziegelbauer, Alan Cuthbertson
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 855.
https://doi.org/10.1158/1538-7445.AM2018-855
Published: 01 July 2018
View articletitled, Abstract 855: Increased in vitro potency and in vivo efficacy of FGFR2-targeted thorium-227 conjugate (FGFR2-TTC) in combination with the ATR inhibitor BAY 1895344
Journal Articles

Abstract 849: Synergistic effect of MSLN-TTC in combination with DNA damage response inhibitors

Katrine Wickstroem, Urs B. Hagemann, Antje M. Wengner, Alexander Kristian, Christine Ellingsen, Gerhard Siemeister, Roger M. Bjerke, Jenny Karlsson, Olav B. Ryan, Lars Linden, Bertolt Kreft, Dominik Mumberg, Hanno Wild, Karl Ziegelbauer, Alan Cuthbertson
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 849.
https://doi.org/10.1158/1538-7445.AM2018-849
Published: 01 July 2018
View articletitled, Abstract 849: Synergistic effect of MSLN-TTC in combination with DNA damage response inhibitors
Journal Articles

Abstract 844: Preclinical activity of PSMA-TTC, a targeted alpha therapeutic in patient-derived prostate cancer models

Stefanie Hammer, Urs B. Hagemann, Sabine Zitzmann-Kolbe, Aasmund Larsen, Christine Ellingsen, Oliver von Ahsen, Jenny Karlsson, Roger M. Bjerke, Olav B. Ryan, Pascale Lejeune, Hartwig Hennekes, Alan Cuthbertson, Karl Ziegelbauer, Dominik Mumberg
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 844.
https://doi.org/10.1158/1538-7445.AM2018-844
Published: 01 July 2018
View articletitled, Abstract 844: Preclinical activity of PSMA-TTC, a targeted alpha therapeutic in patient-derived prostate cancer models
Journal Articles

Abstract 1780: Anetumab ravtansine has single-agent activity in mesothelin-expressing human ovarian cancer models and potentiates the activity of chemotherapeutics and targeted agents

Christoph A. Schatz, Maria Quanz, Urs B. Hagemann, Sabine Zitzmann-Kolbe, Beatrix Stelte-Ludwig, Sven Golfier, Charlotte Kopitz, Cem Elbi, Karl Ziegelbauer, Dominik Mumberg
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1780.
https://doi.org/10.1158/1538-7445.AM2018-1780
Published: 01 July 2018
View articletitled, Abstract 1780: Anetumab ravtansine has single-agent activity in mesothelin-expressing human ovarian cancer models and potentiates the activity of chemotherapeutics and targeted agents
Journal Articles

Abstract 850: Mesothelin targeted thorium-227 conjugate (MSLN-TTC): Preclinical evaluation of a new targeted alpha therapeutic in mesothelin-positive cancers

Urs B. Hagemann, Alexander Kristian, Christine Ellingsen, Katrine Wickstroem, Anne Mobergslien, Jenny Karlsson, Roger M. Bjerke, Christoph Schatz, Christoph Kneip, Joachim Schuhmacher, Liv-Ingrid Oedegaardstuen, Hartwig Hennekes, Anna Tafuri, Dominik Mumberg, Hanno Wild, Karl Ziegelbauer, Alan S. Cuthbertson
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 850.
https://doi.org/10.1158/1538-7445.AM2018-850
Published: 01 July 2018
View articletitled, Abstract 850: Mesothelin targeted thorium-227 conjugate (MSLN-TTC): Preclinical evaluation of a new targeted alpha therapeutic in mesothelin-positive cancers
Journal Articles

Abstract 5857: HER2-targeted thorium-227 conjugate (HER2-TTC): Efficacy in a HER2 positive orthotopic bone model

Jenny Karlsson, Urs B. Hagemann, Christoph Schatz, Derek Grant, Christine Ellingsen, Alexander Kristian, Dessislava Mihaylova, Steinar R. Uran, Mari Suominen, Roger M. Bjerke, Olav B. Ryan, Carl F. Nising, Dominik Mumberg, Alan Cuthbertson
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5857.
https://doi.org/10.1158/1538-7445.AM2017-5857
Published: 01 July 2017
View articletitled, Abstract 5857: HER2-targeted thorium-227 conjugate (HER2-TTC): Efficacy in a HER2 positive orthotopic bone model
Journal Articles

Abstract 5200: Preclinical pharmacology of the PSMA-targeted thorium-227 conjugate PSMA-TTC: a novel targeted alpha therapeutic for the treatment of prostate cancer

Stefanie Hammer, Aasmund Larssen, Christine Ellingsen, Solene Geraudie, Derek Grant, Baard Indrevoll, Oliver von Ahsen, Alexander Kristian, Urs B Hagemann, Jenny Karlsson, Roger M Bjerke, Olav B Ryan, Dominik Mumberg, Bertolt Kreft, Alan Cuthbertson
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5200.
https://doi.org/10.1158/1538-7445.AM2017-5200
Published: 01 July 2017
View articletitled, Abstract 5200: Preclinical pharmacology of the PSMA-targeted thorium-227 conjugate PSMA-TTC: a novel targeted alpha therapeutic for the treatment of prostate cancer
Journal Articles

Abstract 5199: Preclinical activity of the FGFR2-targeted thorium-227 conjugate in preclinical models of colorectal, gastric and triple-negative breast cancer

Urs B. Hagemann, Anette Sommer, Alexander Kristian, Ellen Wang, Åsmund Larsen, Uta Wirnitzer, Heidrun Ellinger-Ziegelbauer, Steffen Sandmann, Thorsten Poethko, Jenny Karlsson, Roger M. Bjerke, Lars Linden, Bertolt Kreft, Hanno Wild, Alan S. Cuthbertson
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 5199.
https://doi.org/10.1158/1538-7445.AM2017-5199
Published: 01 July 2017
View articletitled, Abstract 5199: Preclinical activity of the FGFR2-targeted thorium-227 conjugate in preclinical models of colorectal, gastric and triple-negative breast cancer